Related Experiment Video

Updated: Jul 14, 2025

An Oncogenic Hepatocyte-Induced Orthotopic Mouse Model of Hepatocellular Cancer Arising in the Setting of Hepatic Inflammation and Fibrosis
00:06

An Oncogenic Hepatocyte-Induced Orthotopic Mouse Model of Hepatocellular Cancer Arising in the Setting of Hepatic Inflammation and Fibrosis

Published on: September 12, 2019

8.9K

Successful second-line treatment with cabozantinib for hepatocellular carcinoma harboring cytoplasmic

Makoto Yamamoto1, Takeshi Terashima1, Tatsuya Yamashita1

  • 1Department of Gastroenterology, Kanazawa University Hospital, Kanazawa, Ishikawa, Japan.

Hepatology Research : the Official Journal of the Japan Society of Hepatology
|October 11, 2023
PubMed

Insights

Comprehensive genomic profiling identified MET amplification in a patient with metastatic hepatocellular carcinoma progressing on atezolizumab plus bevacizumab. Cabozantinib treatment led to significant tumor shrinkage, highlighting profiling

Area of Science:

  • Oncology
  • Genomics
  • Medical Treatment

Background:

  • Hepatocellular carcinoma (HCC) is a primary liver cancer with limited treatment options.
  • First-line treatment for advanced HCC often involves immunotherapy combinations like atezolizumab plus bevacizumab.
  • Disease progression after first-line therapy necessitates effective second-line treatment strategies.

Observation:

  • A 72-year-old male patient with metastatic HCC experienced disease progression 5 months after initiating atezolizumab plus bevacizumab.
  • Comprehensive genomic profiling (CGP) was performed to guide subsequent treatment decisions.

Findings:

  • CGP revealed cytoplasmic mesenchymal-epithelial transition factor (MET) amplification in the patient's tumor.
  • Based on expert recommendation, the patient received cabozantinib as second-line therapy.
  • The patient achieved marked and sustained tumor shrinkage for 6 months following cabozantinib treatment.

Implications:

  • Comprehensive genomic profiling can identify actionable targets for advanced HCC.
  • MET amplification may predict response to MET inhibitors like cabozantinib in HCC.
  • Genomic-guided therapy selection can improve outcomes for HCC patients progressing on first-line immunotherapy.
Keywords:
c-Metcabozantinibcomprehensive genetic profiling testhepatocellular carcinomasecond-line therapy

More Related Videos

Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts10:27

Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts

Published on: July 25, 2020

7.3K
Establishing Dual Resistance to EGFR-TKI and MET-TKI in Lung Adenocarcinoma Cells In Vitro with a 2-step Dose-escalation Procedure09:38

Establishing Dual Resistance to EGFR-TKI and MET-TKI in Lung Adenocarcinoma Cells In Vitro with a 2-step Dose-escalation Procedure

Published on: August 11, 2017

8.9K

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.7K
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.3K